



Description générale

A fixed-dose combination of two nucleoside reverse-transcriptase inhibitors (NRTIs, lamivudine and tenofovir disoproxil fumarate) and a non-nucleoside reverse transcriptase inhibitor (NNRTI, efavirenz) for treatment of human immunodeficiency virus (HIV) disease.

INN	Efavirenz + lamivudine + tenofovir
Codes ATC	J05AR11
Type de médicament	Chemical agent
Historique des statuts LME	Ajouté pour la première fois en 2017 (TRS 1006) pour Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified Modifié en 2021 (TRS 1035) pour Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
Équivalent thérapeutique pour	efavirenz + emtricitabine + tenofovir pour Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
Wikipédia	Efavirenz + lamivudine + tenofovir ↗
DrugBank	Efavirenz ↗, Lamivudine ↗, Tenofovir disoproxil ↗

Recommandations

Section Fixed-dose combinations of antiretrovirals

Oral > Solid: 400 mg + 300 mg + 300 mg (tenofovir disoproxil fumarate, equivalent to 245 mg tenofovir disoproxil)

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

